ACAD · Acadia Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$19.95
+0.06 (+0.30%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$3.44B
Shares
172.31M
Volume · Oct 2
2.56M
Avg daily vol (3M)
1.81M
Acadia Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Acadia Pharmaceuticals Inc (ACAD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.7%
$130.71M
−$27.18M
'22 Q3
22-11-02
▲4.4%
$136.49M
−$41.73M
'22 Q4
23-02-28
▲2.6%
$118.46M
−$43.02M
'23 Q1
23-05-08
▲22.8%
$165.24M
$1.11M
'23 Q2
23-07-18
▲62%
$211.70M
−$65.18M
'23 Q3
23-11-02
▲69.3%
$231.04M
$45.80M
'23 Q4
24-02-27
▲73.8%
$205.83M
$16.55M
'24 Q1
24-05-08
▲46.4%
$241.96M
$33.39M
'24 Q2
24-08-06
▲18.3%
$250.40M
$32.77M
'24 Q3
24-11-06
▲12.4%
$259.60M
$143.74M
'24 Q4
25-02-26
▲18.7%
$244.32M
$18.99M
'25 Q1
25-05-07
▲9.3%
$264.57M
$26.67M
'25 Q2
25-08-06
▲11.3%
$278.63M
$71.78M
'25 Q3
25-11-05
▲9.4%
$283.99M
$273.57M
'25 Q4
26-02-25
▲9.7%
$268.06M
$3.64M
'26 Q1
26-05-06
LATEST
▲16.4%
$307.96M
$31.50M
'26 Q2
26-08-04
Conference
Investor event
2026-08-12
Acadia Pharmaceuticals Inc (ACAD) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Acadia Pharmaceuticals Inc (ACAD) Q2 2026 Earnings Call Transcript
Confident tone
Debut (trofinetide) commercial performance
Remlafanserin (ADP) pipeline
New Placid (NUPLAZID/pimavanserin) commercial performance
Revenue
$307.96M
▲ 16.4% YoY Diluted EPS
$0.18
▲ 12.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Acadia Pharmaceuticals Inc (ACAD) Q1 2026 Earnings Call Transcript
Confident tone
DAYBUE Commercial Performance and STIX Launch
Remlifanserin Pipeline in Alzheimer's Disease Psychosis
NUPLAZID Franchise Dynamics
Revenue
$268.06M
▲ 9.7% YoY Diluted EPS
$0.02
▼ 81.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Acadia Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Transcript
Confident tone
DAYBUE growth and STIX launch
NUPLAZID commercial momentum and 2026 guidance
Remlifanserin (ACP-204) Phase II readout
Revenue
$283.99M*
▲ 9.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Acadia Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Transcript
Confident tone
DAYBUE commercial momentum
NUPLAZID record performance and field force expansion
IRA / pricing risk on NUPLAZID
Revenue
$278.63M
▲ 11.3% YoY Diluted EPS
$0.42
▲ 110% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Acadia Pharmaceuticals Inc (ACAD) Q2 2025 Earnings Call Transcript
Confident tone
DAYBUE commercial momentum
NUPLAZID growth and DTC campaign
Pipeline and R&D Day
Revenue
$264.57M
▲ 9.3% YoY Diluted EPS
$0.16
▼ 20% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Acadia Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call
Confident tone
DAYBUE commercial momentum and growth outlook
DAYBUE geographic expansion (Europe and rest of world)
NUPLAZID Parkinson's disease psychosis franchise
Revenue
$244.32M
▲ 18.7% YoY Diluted EPS
$0.11
▲ 10% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Acadia Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Transcript
Confident tone
NUPLAZID commercial performance
2025 revenue guidance
Pipeline breadth and R&D Day
Revenue
$259.60M*
▲ 12.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Acadia Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Transcript
Confident tone
DAYBUE commercial performance
NUPLAZID commercial performance
ACP-204 (Alzheimer's disease psychosis)
Revenue
$250.40M
▲ 18.3% YoY Diluted EPS
$0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Acadia Pharmaceuticals Inc (ACAD) Q2 2024 Earnings Call Transcript
Positive tone
DAYBUE commercial performance
NUPLAZID franchise and growth
Prader-Willi syndrome program (ACP-101)
Revenue
$241.96M
▲ 46.4% YoY Diluted EPS
$0.20
▲ 1900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Acadia Pharmaceuticals Inc (ACAD) Q1 2024 Earnings Call Transcript
Positive tone
DAYBUE commercial performance
NUPLAZID franchise growth
Pipeline and late-stage development
Revenue
$205.83M
▲ 73.8% YoY Diluted EPS
$0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Acadia Pharmaceuticals Inc (ACAD) Q4 2023 Earnings Call Transcript
Confident tone
DAYBUE launch and growth
Pipeline and R&D
NUPLAZID commercial franchise
Revenue
$231.04M
▲ 69.3% YoY Diluted EPS
$0.28
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Acadia Pharmaceuticals Inc (ACAD) Q3 2023 Earnings Call Transcript
Revenue
$211.70M
▲ 62% YoY Diluted EPS
$-0.40
Gross margin
93.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-18
Acadia Pharmaceuticals Inc (ACAD) Q2 2023 Earnings Call Transcript
Revenue
$165.24M
▲ 22.8% YoY Diluted EPS
$0.01
Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Acadia Pharmaceuticals Inc (ACAD) Q1 2023 Earnings Call Transcript
Revenue
$118.46M
▲ 2.6% YoY Diluted EPS
$-0.27
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Acadia Pharmaceuticals Inc (ACAD) Q4 2022 Earnings Call Transcript
Revenue
$136.49M
▲ 4.4% YoY Diluted EPS
$-0.26
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Acadia Pharmaceuticals Inc (ACAD) Q3 2022 Earnings Call Transcript
Revenue
$130.71M
▼ 0.7% YoY Diluted EPS
$-0.17
Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Acadia Pharmaceuticals Inc (ACAD) Q2 2022 Earnings Call Transcript
Revenue
$134.56M
▲ 16.8% YoY Diluted EPS
$-0.21
Gross margin
98.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Acadia Pharmaceuticals Inc (ACAD) Q1 2022 Earnings Call Transcript
Revenue
$115.47M
▲ 8.4% YoY Diluted EPS
$-0.70
Gross margin
97.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Acadia Pharmaceuticals Inc (ACAD) Q4 2021 Earnings Call Transcript
Revenue
$130.76M
▲ 8.1% YoY Diluted EPS
$-0.27
Gross margin
98.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript
Revenue
$131.61M
▲ 9.2% YoY Diluted EPS
$-0.09
Gross margin
97.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript
Revenue
$115.22M
▲ 4.6% YoY Diluted EPS
$-0.27
Gross margin
97.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Acadia Pharmaceuticals Inc (ACAD) Q1 2021 Earnings Call Transcript
Revenue
$106.55M
▲ 18.3% YoY Diluted EPS
$-0.42
Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Acadia Pharmaceuticals Inc (ACAD) Q4 2020 Earnings Call Transcript
Revenue
$121.01M
▲ 23.1% YoY Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Acadia Pharmaceuticals Inc (ACAD) Q3 2020 Earnings Call Transcript
Revenue
$120.58M
▲ 27.5% YoY Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Acadia Pharmaceuticals Inc (ACAD) Q2 2020 Earnings Call Transcript
Revenue
$110.10M
▲ 32.3% YoY Gross margin
97.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Acadia Pharmaceuticals Inc (ACAD) Q1 2020 Earnings Call Transcript
Revenue
$90.07M
▲ 43.1% YoY Gross margin
96.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 webcasts
Key facts
CIK
1070494
CUSIP
004225108
13F (30d)
12 filings
9 filers
Visit website
Investor relations